BWV - Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot
- U.S. vaccine maker Blue Water Vaccines ( NASDAQ: BWV ) on Wednesday said it plans to potentially develop a monkeypox shot using its technology, sending its shares surging 22.4% to $3.12 in premarket trading.
- Cincinnati, Ohio.-based BWV said it would develop the vaccine using its norovirus shell and protrusion virus-like particle platform.
- The company is already using the platform to develop vaccines for multiple diseases, including flu and malaria.
- Blue Water's ( BWV ) announcement comes at a time when the current monkeypox outbreak has been declared a public emergency by both the U.S. FDA and the World Health Organization.
- According to the U.S. Centers for Disease Control and Prevention, there are a total of about 12.7K confirmed monkeypox cases as of Aug. 16 across the country.
- The U.S. is using two vaccines for the prevention of monkeypox - Bavarian Nordic's ( OTCPK:BVNKF ) ( OTCPK:BVNRY ) Jynneos shot and Sanofi's ( SNY ) ACAM2000 shot.
- Other vaccine developers targeting monkeypox: Emergent BioSolutions ( EBS ), Chimerix ( CMRX ).
For further details see:
Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot